



16th Executive Board

12-13 June 2012

WHO Headquarters, Salle D

Geneva, Switzerland

Resolution n°6

Transition progress of the UNITAID Paediatric ARV treatment project to Global Fund grants

The Board recognizes the significant gains attained as a result of UNITAID's Paediatric ARV treatment program and notes that the current UNITAID Paediatric ARV treatment project is scheduled to end in December 2012.

The UNITAID Board reaffirms its commitment to access to Paediatric ARV treatment and diagnostics.

The Board recalls the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM) Board decision adopted at the 23rd GFATM Board Meeting in May 2011, requesting the GFATM Secretariat to facilitate the "provision of support to principal recipients to sustain Paediatric ARV treatment" [GF/B23/DP21].

The Board acknowledges the ongoing work to transition the program to the GFATM but notes that there is a need to secure funding from GFATM for 2013 and beyond for certain specific countries currently funded by UNITAID.

The Board requests the Chair of the Board and the Executive Director of UNITAID to hold high-level discussions with the Chair of the GFATM Board with a view to encouraging the GFATM to make a decision, in the context of its new financing framework, that will mitigate the risks of stock-outs in 2013 and provide UNITAID with visibility regarding any funding shortfall for 2013.

A handwritten signature in black ink, appearing to read "P. Douste-Blazy".

Philippe Douste-Blazy